Associate Vice President, Genetic Nanomedicine
Eli Lilly
Boston, Massachusetts
Michelle Lynn Hall graduated Summa Cum Laude with her B.S. in Chemistry in 2006 from the University of Texas at Austin. She completed her Ph.D. at Columbia in 2011 where she studied quantum chemistry. She subsequently completed a joint post-doc at Novartis and Yale where she studied computer-aided drug design. She worked as a Principal Scientist at Schrödinger from 2012-2016 where she researched molecular simulation and chemical biology. She then joined Moderna where she led the Molecular Engineering and Modeling team and explored everything from mRNA design, protein engineering, and lipid nanoparticle delivery. Michelle was named a “Talented 12” Chemical and Engineering News in 2019 for her work on understanding genetic nanomedicines’ structure and function. Michelle served as an elected officer of the American Chemical Society from 2018-2020. She joined Eli Lilly three years ago, where she leads the Genetic Nanomedicine team in Cambridge, MA exploring all things related to nucleic acids and their delivery. She is passionate about equity, diversity, inclusion, and awareness in science, technology, engineering, and math (STEM) and has served as a mentor, champion, and advocate for women and minorities throughout her career. Michelle is an unabashed cat lady, nature nerd, and bookworm.
Keynote: Genetic (Nano) Medicine: State of the Art, Frontiers and Current Research
Tuesday, October 24, 2023
1:30 PM – 2:30 PM ET